靶向 PPP1R14B 通过 Nrf2/CX3CL1 轴恢复 CD8(+) T 细胞浸润,从而克服前列腺癌的免疫治疗耐药
Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8(+) T-cell infiltration via the Nrf2/CX3CL1 axis.
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文。默认按评分排序(权威性 + 新鲜度)。
Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8(+) T-cell infiltration via the Nrf2/CX3CL1 axis.
Lanmodulin-Engineered Outer Membrane Vesicles for Synergistic Targeted Radio-Immunotherapy.
PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate cancer: a next-generation engineering perspective on stem cell-derived i
MEMBER ACCOUNT
登录成功会直接打开下一页。